Kestra Medical Technologies (NASDAQ:KMTS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kestra Medical Technologies (NASDAQ:KMTS) from a sell rating to a hold rating in a research note released on Saturday.

A number of other equities research analysts have also issued reports on the company. Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research note on Wednesday, July 15th. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. BTIG Research increased their price objective on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Finally, Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and a consensus target price of $28.14.

Kestra Medical Technologies Stock Performance

NASDAQ:KMTS opened at $28.35 on Friday. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -11.71 and a beta of 0.58. The firm’s fifty day simple moving average is $23.13 and its 200 day simple moving average is $22.60. Kestra Medical Technologies has a twelve month low of $14.40 and a twelve month high of $30.00.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. As a group, equities research analysts expect that Kestra Medical Technologies will post -2.29 earnings per share for the current fiscal year.

Insider Buying and Selling at Kestra Medical Technologies

In related news, insider Alfred J. Ford, Jr. sold 6,275 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $24.09, for a total value of $151,164.75. Following the transaction, the insider owned 99,564 shares in the company, valued at approximately $2,398,496.76. The trade was a 5.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Vaseem Mahboob sold 6,995 shares of the stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $24.68, for a total value of $172,636.60. Following the completion of the transaction, the chief financial officer directly owned 86,896 shares of the company’s stock, valued at $2,144,593.28. This represents a 7.45% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 211,877 shares of company stock valued at $4,922,844. Company insiders own 5.30% of the company’s stock.

Institutional Trading of Kestra Medical Technologies

Hedge funds have recently made changes to their positions in the stock. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies during the 4th quarter valued at $31,000. Russell Investments Group Ltd. increased its position in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock worth $41,000 after purchasing an additional 474 shares during the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Kestra Medical Technologies in the 4th quarter valued at about $72,000. BNP Paribas Financial Markets lifted its position in shares of Kestra Medical Technologies by 148.9% during the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock worth $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Brown Brothers Harriman & Co. grew its stake in Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after purchasing an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.